Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.

A, Kling; P, Lukat; DV, Almeida; A, Bauer; E, Fontaine; S, Sordello; N, Zaburannyi; J, Herrmann; SC, Wenzel; C, König; NC, Ammerman; MB, Barrio; K, Borchers; F, Bordon-Pallier; M, Brönstrup; G, Courtemanche; M, Gerlitz; M, Geslin; P, Hammann; DW, Heinz; H, Hoffmann; S, Klieber; M, Kohlmann; M, Kurz; C, Lair; H, Matter; E, Nuermberger; S, Tyagi; L, Fraisse; JH, Grosset; S, Lagrange; R, Müller

doi:10.1126/science.aaa4690

Public

Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.

Published in Science (New York, N.Y.) • Jun 1, 2015

Authors:

Kling A

Lukat P

Almeida DV

Abstract

The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy. Despite the subsequent development of a curative regimen for this disease, tuberculosis remains a worldwide problem, and the emergence of multidrug-resistant Mycobacterium tuberculosis has prioritized the ne...

View

Paywalled

View Full Text

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Generate AI Take for this paper

Discussions